Anamorelin, an orally administered, high-affinity, selective ghrelin receptor agonist, has exhibited the ability to significantly increase lean body mass in patients with advanced NSCLC, although it did not yield a significant improvement in handgrip strength [45]. Here, GHSR is linked to non-small cell lung carcinoma.